SCHEMBL10067359

SCHEMBL10067359

Cc1c(C(C)(C)C)[nH]c2ccc(C(C)C)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.44
▸ GAA P10253 1/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ KIF11 P52732 1/20 0.44
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ HTR1D P28221 2/20 0.38
▸ MAPT P10636 3/20 0.37
▸ HTT P42858 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ UBE2N P61088 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HTR1B P28222 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ TRPA1 O75762 1/20 0.34
▸ PTGS1 P23219 1/20 0.34
▸ CACNA1C Q13936 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17249528 0.79 KDM4E (0.56) KDM4EGAAKIF11NPC1RAB9A
SCHEMBL25815600 0.79 MEN1 (0.49) KDM4EGAAMEN1KMT2AKIF11
SCHEMBL29954050 0.78 KDM4E (0.41) KDM4EGAAMEN1KMT2AKIF11
SCHEMBL10067362 0.77 MEN1 (0.59) MEN1KMT2AKIF11NPC1RAB9A
SCHEMBL22330351 0.76 LMNA (0.50) GAAMEN1KMT2ANPC1RAB9A
SCHEMBL10067361 0.76 KMT2A (0.50) KDM4EGAAMEN1KMT2AKIF11
SCHEMBL10067389 0.76 LMNA (0.49) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL21376875 0.76 KIF11 (0.62) KDM4EGAAMEN1KMT2AKIF11
SCHEMBL16743512 0.75 KIF11 (0.62) KDM4EGAAKIF11HTR1DMAPT
SCHEMBL10067388 0.73 NPC1 (0.44) KDM4EMEN1KMT2AKIF11NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 — — US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 KDM4E 155/4885GAA 4343/4885MEN1 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback